Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

Mukesh Kumar1, Vinicius Ernani1, Taofeek K Owonikoko1

  • 1Department of Hematology & Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Molecular Aspects of Medicine
|July 19, 2015
PubMed

Insights

Advances in genomic interrogation have spurred targeted therapies for lung cancer. Non-small cell lung cancer (NSCLC) subtypes, unlike small cell lung cancer (SCLC), are increasingly classified by molecular and histologic features for personalized treatment.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Lung cancer treatment has advanced significantly due to improved genomic analysis.
  • Historically, lung cancer was broadly classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • NSCLC has been further subcategorized based on histology and molecular profiles.

Purpose of the Study:

  • To highlight the evolution of lung cancer subtyping.
  • To emphasize the role of molecular and histologic characteristics in NSCLC treatment.
  • To underscore the impact of genomic interrogation on developing targeted therapies.

Main Methods:

  • Review of recent advancements in lung cancer genomics.
  • Analysis of subclassification strategies for NSCLC.
  • Correlation of molecular subtypes with therapeutic outcomes.

Main Results:

  • Genomic interrogation has enabled the development of targeted anticancer agents.
  • NSCLC subtyping based on molecular and histologic features is crucial for prognosis.
  • These subtypes guide the selection of effective, biologically rational therapies.

Conclusions:

  • Lung cancer is a heterogeneous disease requiring subtype-specific treatments.
  • Molecular and histologic subtyping of NSCLC is essential for personalized medicine.
  • Technological advancements in genomics are driving innovation in lung cancer therapeutics.
Keywords:
ALKBiomarkersEGFRLung cancerNSCLCRETROS1

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K